Back to Search Start Over

Loss of Y in leukocytes as a risk factor for critical COVID-19 in men

Authors :
Bożena Bruhn-Olszewska
Hanna Davies
Daniil Sarkisyan
Ulana Juhas
Edyta Rychlicka-Buniowska
Magdalena Wójcik
Monika Horbacz
Marcin Jąkalski
Paweł Olszewski
Jakub O. Westholm
Agata Smialowska
Karol Wierzba
Åsa Torinsson Naluai
Niklas Jern
Lars-Magnus Andersson
Josef D. Järhult
Natalia Filipowicz
Eva Tiensuu Janson
Sten Rubertsson
Miklós Lipcsey
Magnus Gisslén
Michael Hultström
Robert Frithiof
Jan P. Dumanski
Source :
Genome Medicine, Vol 14, Iss 1, Pp 1-14 (2022)
Publication Year :
2022
Publisher :
BMC, 2022.

Abstract

Abstract Background The COVID-19 pandemic, which has a prominent social and economic impact worldwide, shows a largely unexplained male bias for the severity and mortality of the disease. Loss of chromosome Y (LOY) is a risk factor candidate in COVID-19 due to its prior association with many chronic age-related diseases, and its impact on immune gene transcription. Methods Publicly available scRNA-seq data of PBMC samples derived from male patients critically ill with COVID-19 were reanalyzed, and LOY status was added to the annotated cells. We further studied LOY in whole blood for 211 COVID-19 patients treated at intensive care units (ICU) from the first and second waves of the pandemic. Of these, 139 patients were subject to cell sorting for LOY analysis in granulocytes, low-density neutrophils (LDNs), monocytes, and PBMCs. Results Reanalysis of available scRNA-seq data revealed LDNs and monocytes as the cell types most affected by LOY. Subsequently, DNA analysis indicated that 46%, 32%, and 29% of critically ill patients showed LOY above 5% cut-off in LDNs, granulocytes, and monocytes, respectively. Hence, the myeloid lineage that is crucial for the development of severe COVID-19 phenotype is affected by LOY. Moreover, LOY correlated with increasing WHO score (median difference 1.59%, 95% HDI 0.46% to 2.71%, p=0.025), death during ICU treatment (median difference 1.46%, 95% HDI 0.47% to 2.43%, p=0.0036), and history of vessel disease (median difference 2.16%, 95% HDI 0.74% to 3.7%, p=0.004), among other variables. In 16 recovered patients, sampled during ICU stay and 93–143 days later, LOY decreased significantly in whole blood and PBMCs. Furthermore, the number of LDNs at the recovery stage decreased dramatically (median difference 76.4 per 10,000 cell sorting events, 95% HDI 55.5 to 104, p=6e−11). Conclusions We present a link between LOY and an acute, life-threatening infectious disease. Furthermore, this study highlights LOY as the most prominent clonal mutation affecting the myeloid cell lineage during emergency myelopoiesis. The correlation between LOY level and COVID-19 severity might suggest that this mutation affects the functions of monocytes and neutrophils, which could have consequences for male innate immunity.

Subjects

Subjects :
Medicine
Genetics
QH426-470

Details

Language :
English
ISSN :
1756994X
Volume :
14
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Genome Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.47e00c830df04f0b876d13cf816381e5
Document Type :
article
Full Text :
https://doi.org/10.1186/s13073-022-01144-5